An interventional study of Exercise in Overweight and Obesity, sponsored by University of Glasgow. Status unknown at 1 site in United Kingdom. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-17.
Sponsored by University of Glasgow · Not applicable, Interventional, and Other
Among 452 studies in Obesity with a site in United Kingdom — 92 open to participants now, 126 under way, 39 of them phase 3. Obesity · United Kingdom.
Among the 452 studies in Obesity with a site in United Kingdom, this one is the 192nd largest by planned enrollment of the 370 interventional ones that give a count, is one of 19 that started in 2015, is one of 225 with no phase, and was the 167th registered.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
Browse Obesity studies →92 of the 452 studies in Obesity with a site in United Kingdom are open now. Recruiting first, the newest first:
Elenzia · Sites in United Kingdom
StudySetGo · Sites in United Kingdom
Ascletis Pharma (China) Co., Limited · Sites in United Kingdom, United States, Canada and 4 more countries
Ascletis Pharma (China) Co., Limited · Sites in United Kingdom, United States, Czechia and 3 more countries
AstraZeneca · Sites in United Kingdom, United States, Argentina and 8 more countries
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 168 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
452 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 36 · Phase 3 75 · Phase 4 12
First in 2001; this study’s year is marked. 19 started in 2015.
This study's planned enrollment of 60 is below the median of 67 across 9,006 interventional studies indexed under Obesity.
Median enrollment 65 across the 370 interventional studies, 130 across the 81 observational. Of the 272 that completed or were terminated, 52 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
139 of 452 have an industry lead sponsor. The 10 most frequent:
University of Glasgow is the lead sponsor of 145 studies on the registry; 21 are open to participants now.
University of Glasgow has 8 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
29 of the studies in Obesity with a site in United Kingdom that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
Among the 452 studies in Obesity with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evidence suggests that gut microbiota contributes to the development of atherosclerosis and therefore CVDs. Exercise has been extensively reported to be protective against CVDs due to modification of body fatness, metabolic risk factors and cardio-respiratory fitness. It remains unclear whether impact of exercise on CVD risk can be at least in part explained by changes in the microbiota. It also remains to be investigated whether modification of appetite and appetite hormones due to participation in exercise are related to changes in the gut microbiota composition. Therefore, this study will be conducted in overweight, healthy, sedentary women and will investigate the effect of a 4-week moderate intensity exercise programme on gut microbiota composition and metabolic activity, plasma concentrations of fasting and postprandial lipids, glucose, insulin and inflammatory markers, fasting and postprandial gut appetite hormones, subjective appetite measures and cardio-respiratory fitness.
Study Design: This is a randomized controlled study with a parallel design. Healthy, sedentary females aged between 18-45 years old will be recruited by means of an advertisement leaflet and word of mouth. Eligible participants will be enrolled in the study and will be randomly allocated to either exercise intervention (EX) or control (C) groups. The EX group will participate in a 4-week exercise intervention and the C group will be asked to continue with habitual life style for 4 weeks. Before and after 4 weeks of the intervention, participants from both groups will be asked to conduct a submaximal exercise test and a 7-hour experimental trial during which blood samples will be collected and metabolic rate will measured before and after consumption of standardized breakfast and lunch. Prior to the first 7-hour trial, participants will be asked to record diet for 3 days and replicate this diet prior to the second 7-hour trial. During these 3 days participants will provide fresh stool samples. Participants allocated to control group will have the option to participate in exercise intervention. A subset of the participants will repeat a 7-hour experimental trial and provide fresh stool and urine sample after 7 days of detraining.
Methods:
Preliminary Health Check: Participants will undertake a health screening questionnaire on the day of recruitment. Participants will also need to fill in Physical Activity Readiness Questionnaire (PARQ). Only participants who answered "no" to all questions in PARQ will conduct the submaximal exercise test.
Anthropometry: All participants will have height, weight and waist circumference measured at baseline and 4 weeks after the intervention.
7-hour Experimental Trial: Participants will attend the metabolic suite (New Lister Building, Glasgow Royal infirmary) in a fasted state at approximately 9.00 am. Participants will be instructed to lie supine on the couch, with the head resting on the pillow provided. Resting metabolic rate will be measured for 20 minutes and fasting blood sample will be obtained. A breakfast meal will be consumed immediately after the fasting sample and a lunch meal after 4 hours. Blood samples will be taken throughout a cannula hourly after breakfast and lunch consumption. Following each blood sample, metabolic rate will be measured for the duration of 20 minutes. Prior each blood sample, participants will fill in appetite questionnaires. Blood samples will be analysed for plasma lipids, glucose, insulin, inflammatory markers and gut appetite hormones using standard existing procedures.
Feacal sample collection \& analysis: A disposable stool sample collection kit will be provided prior to the 7-hour trial day. Once collected, the container is sealed and placed in a larger sealable bag with a reducing sachet to remove oxygen and maintain anaerobic bacteria. Stool samples will be measured for changes in gut microbiota based on 16S rRNA amplicon sequencing, bacterial functional capacity and targeted bacterial metabolites (short chain fatty acids, sulphide, ammonia).
Exercise Training Programme: Exercise training will consist of 4 weekly sessions of endurance type exercise (cycling and running) lasting for 30, 40, 50, 60 minutes in the week 1, 2, 3 and 4 respectively. The time and day of each training trial will be agreed between the investigator and the participant and will be based around the participant's availability. All exercise sessions will be supervised by a researcher.
Submaximal Exercise Test: Participants will exercise on treadmill at gradually increasing intensities until 85% of maximal heart rate. During the last minute of each of the intensities heart rate will be measured and expired air will be collected by Douglas bag technique and analysed for oxygen consumption and carbon dioxide production. Relation between heart rate and rate of oxygen consumption will be used to predict maximal oxygen consumption, a marker of cardio-respiratory fitness.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 60 is below the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →University of Glasgow is the lead sponsor of 145 studies on the registry; 21 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4-week moderate intensity exercise programme
Behavioral: Exercise
4 weeks of habitual life style
4-week moderate intensity exercise programme
Gut microbiota composition
Changes in the gut microbiota composition measured by 16S rRNA amplicon sequencing.
Time frame: 12 months
Interleukin-6 (IL-6)
Changes in fasting and postprandial interleukin-6 pre- and post-interventions measured by Human IL-6 ELISA Ready-Set-Go (Affymetrix, eBioscience)
Time frame: 3 months
Glucose
Changes in fasting glucose pre- and post-interventions measured by Randox Glucose
Time frame: 3 months
Triglycerides
Changes in fasting and postprandial triglycerides pre- and post-interventions measured by Randox Triglycerides
Time frame: 3 months
Insulin
Changes in fasting insulin pre- and post-interventions measured by Mercodia Insulin ELISA
Time frame: 3 months
Peptide YY (PYY)
Changes in fasting and postprandial peptide YY pre- and post-interventions measured by Human PYY (Total) ELISA (Merc Millipore)
Time frame: 12 months
Glucagon-like peptide-1 (GLP-1)
Changes in fasting and postprandial glucagon-like peptide-1 pre- and post-interventions measured by GLP-1 Total ELISA (Merc Millipore)
Time frame: 12 months
Subjective appetite
Changes in subjective appetite (hunger, satiety, fullness, prospective food consumption, desire to eat) pre- and post-interventions measured by Visual Analogue Scales (VAS) where respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points (minimum score is 0 and maximum score is 100)
Time frame: 12 months
Faecal short-chain fatty acids
Changes in concentrations of feacal short-chain fatty acids pre- and post-interventions measured by TRACE 2000 Gas Chromatography (ThermoQuest Ltd)
Time frame: 12 months
Faecal pH
Changes in feacal pH between pre- and post-intervention measured by Hanna HI 98140
Time frame: 1 month
Body weight
Differences in body weight (kilograms) between pre- and post-intervention measured by TANITA scales (TBF-300)
Time frame: 1 month
Height
Height (meters) measured by stadiometer, a vertical ruler with a sliding horizontal paddle which is adjusted to rest on the top of the head
Time frame: 1 month
Body fat (kilograms)
Differences in body fat expressed in kilograms between pre- and post-intervention measured by TANITA scales (TBF-300)
Time frame: 1 month
Body fat (% percentage)
Differences in body fat expressed as percentage (%) (proportion of fat to the total body weight) between pre- and post-intervention measured by TANITA scales (TBF-300)
Time frame: 1 month
Body Mass Index (BMI)
Differences in body mass index (weight and height will be combined to report BMI in kg/m\^2) between pre- and post-intervention measured by TANITA scales (TBF-300)
Time frame: 1 month
Dietary Intake
Energy intake and macro nutrient intake using WinDiets software based on food composition tables
Time frame: 6 months
Maximum Oxygen Consumption
Maximum Oxygen Consumption (ml/kg/min) measured before and after the interventions by Servomex Gas Analyser
Time frame: 2 weeks
Energy substrate oxidation
Fat and carbohydrate oxidation in the fasted and postprandial state measured before and after the interventions using indirect calorimetry (Oxycon Pro)
Time frame: 6 months
Resting Metabolic Rate
Resting metabolic rate was measured before and after the interventions (Oxycon Pro)
Time frame: 2 month
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2015 (actual). Primary completion is estimated for Nov 2017, 26 months after the start.
Of 3,680 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 26 months is above that.
Counting every sponsor, half of 3,843 studies reached it within 22 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.